Why Some People Stay Mentally Fit Despite Alzheimer’s Brain Changes – WELT

Researchers are making progress in understanding why some individuals remain cognitively healthy despite having brain changes associated with Alzheimer’s disease. A growing body of evidence suggests that biological resilience mechanisms may protect against cognitive decline even in the presence of amyloid plaques and other neuropathological markers.

A study led by scientists at the University of California San Diego has identified a potential molecular switch that may help explain this phenomenon. The researchers focused on asymptomatic Alzheimer’s disease (AsymAD), a condition in which individuals exhibit Alzheimer’s-related brain changes but do not show symptoms of memory loss or cognitive impairment.

According to co-senior author Sushil K. Mahata, PhD, adjunct professor of medicine at UC San Diego School of Medicine and research physiologist at the VA San Diego Healthcare System, the findings reveal the brain’s built-in defenses. “Even when the brain shows clear signs of Alzheimer’s, some people stay mentally sharp,” Mahata said. “We’re beginning to uncover the brain’s built-in defenses—and that could fundamentally change how we approach treatment.”

The research, published in April 2026, analyzed gene activity in donated human brain tissue to identify patterns linked to cognitive resilience. By comparing brains with similar levels of Alzheimer’s pathology, the team discovered a distinct gene signal that correlated with preserved cognitive function rather than the extent of disease burden alone.

This gene signal did not simply reflect how much amyloid or tau pathology was present, but whether that pathology was associated with cognitive decline or with maintained mental function. The distinction helped sharpen the focus on biological factors that may determine whether brain damage leads to symptoms.

Additional support for the concept of cognitive resilience comes from a comprehensive review led by the University of New South Wales Sydney’s Centre for Healthy Brain Ageing (CHeBA) in collaboration with Neuroscience Research Australia (NeuRA). Published in The Lancet Neurology in April 2026, the review highlights how advances in brain imaging and blood-based biomarkers now allow researchers to study Alzheimer’s disease and related conditions in living individuals and track their relationship to cognitive function over time.

“Dementia is not an inevitable consequence of brain pathology,” says Professor Henry Brodaty, Co-Director of CHeBA. “Some individuals show remarkable cognitive resilience, maintaining cognitive abilities despite a substantial burden of disease in the brain.” The review emphasizes that modern tools such as neuroimaging, electroencephalography, and cerebrospinal fluid and blood biomarkers are transforming dementia research by enabling earlier detection and monitoring of resilience factors.

Further research from UC San Diego, reported by Earth.com in April 2026, points to a stress-related protein that may play a role in resisting Alzheimer’s decline. Using computer models to analyze gene activity across multiple brain datasets, researchers identified a pattern in donated human brain tissue that distinguished normal aging, dementia, and a state in which Alzheimer’s pathology was present but had not yet affected memory or thinking.

This asymptomatic state affects an estimated 20 to 30 percent of older adults with Alzheimer’s-related brain changes. In 2026, an estimated 7.4 million Americans aged 65 and older were living with Alzheimer’s dementia, with women accounting for nearly two-thirds of cases. Understanding why a significant subset avoids symptoms despite similar pathology could inform new strategies for early detection, prevention, and treatment.

While the exact mechanisms underlying cognitive resilience remain under investigation, researchers agree that identifying protective pathways offers promise for interventions that could support brain health in aging populations. Ongoing work aims to translate these findings into clinical applications that may help delay or prevent the onset of cognitive decline, even in those with biological signs of Alzheimer’s disease.